Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy

Abraham S Kanate; Navneet Majhail; Zachariah DeFilipp; Binod Dhakal; Bhagirathbhai Dholaria; Betty Hamilton; Alex F Herrera; Yoshihiro Inamoto; Tania Jain; Miguel-Angel Perales; Paul A Carpenter; Mehdi Hamadani

doi:10.1016/j.jtct.2023.07.002

Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy

Transplant Cell Ther. 2023 Oct;29(10):594-597. doi: 10.1016/j.jtct.2023.07.002. Epub 2023 Jul 6.

Authors

Affiliations

¹ HonorHealth Cancer Transplant Institute, Scottsdale, Arizona. Electronic address: akanate@honorhealth.com.
² Sarah Cannon Transplant and Cellular Therapy Network, Nashville, Tennessee.
³ Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, Massachusetts.
⁴ BMT & Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, Wisconsin.
⁵ Department of Hematology- Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.
⁶ Blood and Marrow Transplant Program, Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
⁷ Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, California.
⁸ Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
⁹ Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
¹⁰ Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York.
¹¹ Clinical Research Division, Fred Hutch Cancer Center, Seattle, Washington.

PMID: 37422194
DOI: 10.1016/j.jtct.2023.07.002

Abstract

The American Society for Transplantation and Cellular Therapy (ASTCT) published its guidelines on indications for autologous and allogeneic hematopoietic cell transplantation (HCT) and immune effector cell therapy (IECT) in 2020. Since then, we have witnessed rapid advancements in the field of IECT, resulting in several new chimeric antigen receptor T cell (CAR-T) products and disease indications being approved by the US Food and Drug Administration (FDA). To keep abreast of these practice changes, the ASTCT Committee on Practice Guidelines commissioned a focused update covering CAR-T therapy indications. Here we present updated ASTCT recommendations on indications for CAR-T therapy. Only FDA-approved indications for CAR-T were recommended and categorized as "standard of care," where the indication is well defined and supported by evidence. The ASTCT will continue to periodically review these guidelines and update them as new evidence becomes available.

Keywords: Chimeric antigen receptor T cells; Immune effector cell therapy; Indications.

Publication types

Practice Guideline